scholarly journals Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative

2021 ◽  
Author(s):  
Francesc Bosch ◽  
Blanca Navarro ◽  
Marta Crespo ◽  
Miguel Alcoceba ◽  
Julio Bravo Sánchez ◽  
...  
Keyword(s):  
Lymphocytic Leukemia ◽  
Molecular Testing ◽  
Therapeutic Decision ◽  
National Network ◽  
Mutational Status ◽  
Net Promoter Score ◽  
Net Promoter ◽  
Therapeutic Decision Making ◽  
Influential Parameters ◽  
Testing Reference

AbstractAmong the different biomarkers predicting response in chronic lymphocytic leukemia (CLL), the most influential parameters are the mutational status of the IGHV genes and the presence of TP53 gene disruptions. Nevertheless, these important assessments are not readily available in most centers dealing with CLL patients. To provide this molecular testing across the country, the Spanish Cooperative Group on CLL (GELLC) established a network of four analytical reference centers. A total of 2153 samples from 256 centers were analyzed over a period of 30 months. In 9% of the patients, we found pathological mutations in the TP53 gene, whereas 48.96% were classified as IGHV unmutated. Results of the satisfaction survey of the program showed a Net Promoter Score of 85.15. Building a national network for molecular testing in CLL allowed the CLL population a broad access to complex biomarkers analysis that should translate into a more accurate and informed therapeutic decision-making.

The role of cytogenetic and molecular testing in the diagnostics and prognostication of chronic B-cell lymphocytic leukemia

2021 ◽  
Vol 56 (3) ◽  
pp. 1-17
Author(s):  
Marta Szarawarska ◽  
Andrzej Jasiewicz ◽  
Andrzej Pluta ◽  
Joanna Niemiec
Keyword(s):  
B Cell ◽  
Predictive Factors ◽  
Chromosomal Abnormalities ◽  
Adult Population ◽  
Clinical Stage ◽  
Tp53 Gene ◽  
Lymphocytic Leukemia ◽  
Molecular Testing ◽  
Mutational Status ◽  
Risk Patients

B-cell chronic lymphocytic leukemia (B-CLL) is the most frequently diagnosed leukemia in an adult population in Europe and North America. Disease pathogenesis is not well defined. The majority patients are following the “wait and watch” strategy since early treatment does not affect survival. The therapeutic decision is based on the clinical stage of disease, presence of comorbid conditions clinical disease activity as well as 11q deletion and 17p deletion status and/or mutation in the TP53 gene. Moreover, expression of CD38, ZAP70, and mutational status of IGVH gene are well-known prognostic factors. The following chromosomal abnormalities are the most frequently diagnosed in CLL: 13q14 (in 50 – 60% CLL), 11q22-23 (in 12 – 18% CLL), 17p13 (in 10% CLL) deletion, 6q (in about 6% CLL) and trisomy of chromosome 12 (in 10 – 20% CLL). However, the above-mentioned factors are not able to define all, high-risk patients. Therefore, there is an urgent need to search for new prognostic and predictive factors, which might be helpful in better classification and selection for personalized therapy for B-cell CLL patients. This prompted us to review both the well-known and new prognostic/predictive factors.

Effect of the 92-gene molecular classifier on therapeutic decision-making in cancers of uncertain primary.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e15130-e15130
Author(s):  
Brock Schroeder ◽  
Catherine A. Schnabel ◽  
Mark G. Erlander ◽  
Benjamin Kim
Keyword(s):  
Decision Making ◽  
Clinical Diagnosis ◽  
Clinical Utility ◽  
Metastatic Cancer ◽  
Clinical Care ◽  
Molecular Testing ◽  
Tumor Type ◽  
Therapeutic Decision ◽  
Gene Assay ◽  
Therapeutic Decision Making

e15130 Background: Patients with metastatic cancer of uncertain primary site are at risk of suboptimal therapy if tumor type and subtype cannot be determined. Gene expression-based assays for tumor classification are utilized to complement clinicopathologic evaluation in cases with unknown primary sites of tumor origin or differential diagnoses; however, few studies have evaluated their clinical utility and effectiveness in real-world practice. The objective of this study was to evaluate the influence of a 92-gene molecular classification assay on clinical diagnosis and therapeutic decision-making. Methods: Medical oncologists who ordered the 92-gene assay as part of clinical care were invited to participate in a retrospective, questionnaire-based study. To minimize selection and recall biases, recruitment was based on consecutive cases: participating physicians were instructed to review the medical record of the first patient they ordered the 92-gene assay after a specified date and subsequently complete a 61-question survey. Results: Of 1,105 physicians invited, 103 (9.4%) completed the study (82% community practice; median practice time: 10 years). The majority of respondents had not initiated oncologic treatment before ordering the 92-gene assay: 31% had begun treatment, 24% had a specific regimen chosen but were waiting to begin treatment and 45% had not begun treatment or chosen a specific regimen. The 92-gene assay prediction was concordant with the final clinical diagnosis in 84% of cases; in one-third of these, the molecular diagnosis had not been clinically considered prior to molecular testing. Eighty-one percent of study participants reported that the 92-gene assay helped with therapeutic decision-making. Of these, the assay guided initial treatment choice in 52%, changed a considered treatment in 10%, excluded a potential treatment in 6%, and confirmed a previously determined treatment in 29% of cases. Conclusions: The results of this retrospective study demonstrate the clinical utility of molecular cancer classification: the molecular diagnoses provided by the 92-gene assay influenced therapeutic decision-making in the majority of cases.

KLIENT W CYFROWYM ŚWIECIE — DOŚWIADCZENIA NIEMIECKIEJ BRANŻY UBEZPIECZENIOWEJ

2018 ◽  
pp. 51-58
Author(s):  
Judyta Przyłuska-Schmitt
Keyword(s):  
Big Data ◽  
Net Promoter Score ◽  
Net Promoter

Celem artykułu jest określenie wpływu digitalizacji branży ubezpieczeniowej na zadowolenie klientów. A dokładniej, w jaki sposób proces zmian, spowodowany potrzebą wzmocnienia użyteczności technologii cyfrowej, wpływa na działalność niemieckiego sektora ubezpieczeniowego w budowaniu nowej jakości relacji z klientem. Artykuł opiera się na analizie literatury przedmiotu i zagadnień dotyczących koncepcji budowania relacji z klientem w sieci. Efekty procesu zmian zachodzących na rynku pod wpływem rozwoju i wykorzystania nowych technologii odczuwają wszyscy uczestnicy życia gospodarczego, a zwłaszcza branża ubezpieczeniowa, która jest szczególnie predystynowana w tym zakresie. Dzięki wykorzystaniu Big Data i metody Net Promoter Score ubezpieczyciele mogą w sposób efektywny oferować wartość dodaną swoim klientom oraz dbać o własną markę i lojalność klienta. Przedstawione w artykule treści podkreślają zarówno nowe możliwości wykorzystania w branży ubezpieczeniowej nowoczesnych technologii do budowania nowych jakości interakcji z klientem, jak też wskazują potrzebę dostosowania się do rzeczywistości podyktowanej oczekiwaniami społeczeństwa informacyjnego.

Enabling Customer-Centricity and Relationship Management using Net Promoter Score

2018 ◽  
Vol 9 (2) ◽  
pp. 115-126 ◽  
Author(s):  
Nicoleta Valentina Florea ◽  
Dorina Antoneta Tănăsescu ◽  
Anişoara Duică
Keyword(s):  
Relationship Marketing ◽  
Performance Indicators ◽  
Simulation Modeling ◽  
Customer Value ◽  
Future Trends ◽  
New Methods ◽  
Net Promoter Score ◽  
Net Promoter ◽  
Customer Centricity ◽  
Loyal Customers

Abstract We are in the fifth era of marketing development, that of relationship marketing, where the environment is influenced by globalization, informatization, market liberalization, and the overcapacity of production, and the focus will be not on increasing the volume of production, but on obtaining profit using relationship with profitable customers. Customer-centricity, customization, one-to-one relationship and measuring the value of each customer is an advantage in the fearless market. Organizations if they knew what customers wants would offering only those products or services they want, but to help them to know the customers’ needs better, they use models, new methods and calculation of performance indicators. One of the models which help organizations to determine the customer value and centricity is Net Promoter Score (NPS), its formula being developed by Reichheld F. in 2006. Our research is made on 10 organizations and on 150 respondents and is consisting in using NPS in order to observe customers’ perception of the analysed brands, to measure how well the brand is having satisfayed and loyal customers, and the desire for recommendation of the analysed brand. Our article is using simulation, modeling and IT programs to observe possible relationships and future trends.

scholarly journals Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia

2001 ◽  
Vol 194 (11) ◽  
pp. 1639-1648 ◽  
Author(s):  
Andreas Rosenwald ◽  
Ash A. Alizadeh ◽  
George Widhopf ◽  
Richard Simon ◽  
R. Eric Davis ◽  
...  
Keyword(s):  
Gene Expression ◽  
Chronic Lymphocytic Leukemia ◽  
B Cell ◽  
Germ Line ◽  
Gene Expression Signature ◽  
Lymphocytic Leukemia ◽  
Common Mechanism ◽  
Human Leukemia ◽  
Mutational Status ◽  
Cell Chronic Lymphocytic Leukemia

The most common human leukemia is B cell chronic lymphocytic leukemia (CLL), a malignancy of mature B cells with a characteristic clinical presentation but a variable clinical course. The rearranged immunoglobulin (Ig) genes of CLL cells may be either germ-line in sequence or somatically mutated. Lack of Ig mutations defined a distinctly worse prognostic group of CLL patients raising the possibility that CLL comprises two distinct diseases. Using genomic-scale gene expression profiling, we show that CLL is characterized by a common gene expression “signature,” irrespective of Ig mutational status, suggesting that CLL cases share a common mechanism of transformation and/or cell of origin. Nonetheless, the expression of hundreds of other genes correlated with the Ig mutational status, including many genes that are modulated in expression during mitogenic B cell receptor signaling. These genes were used to build a CLL subtype predictor that may help in the clinical classification of patients with this disease.

Sign in / Sign up

Export Citation Format

Share Document